Last viewed: ORTX

Prices are updated after-hours

ORTX Nasdaq

Orchard Therapeutics plc

ORTX | $16.7 0.0% 370K

|

Health Technology

(0.0% 1d) (0.0% 1m) (252.3% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-100.0% volume)
Earnings Calendar:
Market Cap: $ 38,010,937
http://orchard-tx.com
Sec Filling | Patents | 252 employees

(United Kingdom) Orchard Therapeutics Plc is a biopharmaceutical company, which engages in discovering, acquiring, developing and commercializing gene therapies for patients with rare disorders. The company focuses on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, a commercial-stage gamma retroviral-based product for the treatment of Adenosine deaminase deficiency (ADA-SCID). The company was founded by Nicolas Koebel and Andrea Spezzi in August 2018 and is headquartered in London, the United Kingdom.

gene therapies urea treatment

add to watch list Paper trade email alert is off

Press-releases

Orchard Therapeutics Outlines U.S. Launch Plans for Lenmeldy™ (atidarsagene autotemcel), the Only Approved Therapy for Children with Early-onset Metachromatic Leukodystrophy
Published: 2024-03-20 (Crawled : 11:00) - globenewswire.com
ORTX | $16.7 0.0% 370K

|

Health Technology

| Email alert Add to watchlist
children approved therapeutics therapy

Orchard Therapeutics Receives FDA Approval of Lenmeldy™ (atidarsagene autotemcel), the Only Therapy for Eligible Children with Early-onset Metachromatic Leukodystrophy in the U.S.
Published: 2024-03-18 (Crawled : 20:00) - globenewswire.com
ORTX | $16.7 0.0% 370K

|

Health Technology

| Email alert Add to watchlist
fda children approval therapeutics therapy

Orchard Therapeutics Announces First Patient Randomized in Registrational Trial of OTL-203 for MPS-I Hurler Syndrome
Published: 2024-02-05 (Crawled : 12:00) - globenewswire.com
ORTX | $16.7 0.0% 370K

|

Health Technology

| Email alert Add to watchlist
otl-203 first mps-i trial therapeutics

Orchard Therapeutics Announces Multiple Presentations at the 20th Annual WORLDSymposium
Published: 2024-02-02 (Crawled : 12:00) - globenewswire.com
ORTX | $16.7 0.0% 370K

|

Health Technology

| Email alert Add to watchlist
therapeutics

Orchard Therapeutics Announces Agreement with the Beneluxa Consortium Enabling Reimbursed Access to Libmeldy
Published: 2024-01-25 (Crawled : 12:00) - globenewswire.com
ORTX | $16.7 0.0% 370K

|

Health Technology

| Email alert Add to watchlist
libmeldy enabling therapeutics agreement

Soleno Therapeutics Strengthens Leadership Team with Key Appointments
Published: 2024-01-24 (Crawled : 13:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 600K

|

Health Technology

| -10.09% | O: -3.01% H: 0.69% C: -0.75%
VYGR | News | $7.57 0.93% 0.92% 320K

|

Health Technology

| 0.0% | O: 1.19% H: 0.33% C: -2.61%
SLNO | $37.65 0.4% 0.19% 370K

|

Health Technology

| -21.91% | O: -1.62% H: 1.53% C: -2.07%
SNY | News | $47.125 1.78% 1.75% 2.1M

|

Health Technology

| -7.6% | O: 0.92% H: 0.0% C: 0.0%
PIRS | $0.1461 0.76% 0.75% 1.8M

|

Health Technology

| 6883.27% | O: -3.23% H: 4.2% C: -1.3%
FULC | $7.26 6.14% 5.79% 600K

|

Health Technology

| 7.89% | O: 1.04% H: 2.28% C: -1.33%
key therapeutics

Kyowa Kirin successfully completes acquisition of Orchard Therapeutics, a global gene therapy leader for rare diseases
Published: 2024-01-24 (Crawled : 10:00) - globenewswire.com
ORTX | $16.7 0.0% 370K

|

Health Technology

| Email alert Add to watchlist
rare acquisition global therapy

INVO Bioscience Files S-4 Registration and Preliminary Joint Proxy Statements in Connection with Merger with NAYA Biosciences, NAYA Announces New Board Directors
Published: 2024-01-17 (Crawled : 15:30) - biospace.com/
NBTX | $5.87 8.5% 7.84% 4.5K

|

| -26.91% | O: -0.51% H: 0.0% C: -0.77%
SNYNF | News | $92.7 -2.18% 600K

|

Health Technology

| -10.78% | O: -1.83% H: 0.0% C: 0.0%
VIRX | $0.8567 -3.3% 12K

|

| 62.66% | O: -0.18% H: 0.0% C: -3.33%
INVO | $1.24 -9.49% -10.48% 910K

|

Health Technology

| 18.1% | O: 5.71% H: 10.81% C: 6.31%
JNJ | News | $149.12 0.82% 0.0% 9.3M

|

Health Technology

| -7.91% | O: -1.02% H: 0.0% C: 0.0%
SLN | $22.59 -0.22% -0.22% 170K

|

Health Technology

| 26.05% | O: -1.62% H: 3.08% C: 2.96%
SNY | News | $47.125 1.78% 1.75% 2.1M

|

Health Technology

| -10.44% | O: 0.45% H: 0.06% C: -0.5%
ORTX | $16.7 0.0% 370K

|

Health Technology

| 1.16% | O: -0.3% H: 0.98% C: 0.98%
KYMR | $34.37 1.18% 1.16% 420K

|

Health Technology

| 21.77% | O: -2.8% H: 5.11% C: 1.42%
bioscience

Cellectis Reports Results from Shareholders Meeting Held on December 22, 2023
Published: 2023-12-22 (Crawled : 22:00) - globenewswire.com
CLLS | News | $2.64 3.53% 3.41% 24K

|

Health Technology

| Email alert Add to watchlist
ORTX | $16.7 0.0% 370K

|

Health Technology

| Email alert Add to watchlist
meeting results

Gene therapy market size to grow by USD 4,613.9 million from 2022 to 2027 | North America is estimated to contribute 39% to the growth - Technavio
Published: 2023-12-12 (Crawled : 08:00) - prnewswire.com
ALPMF | News | $9.75 43.47% 200

|

Health Technology

| -18.41% | O: -0.42% H: 0.0% C: 0.0%
NVSEF | News | $93.6375 6.88% 82K

|

Health Technology

| -0.93% | O: 1.56% H: 0.51% C: 0.51%
ALPMY | News | $9.5 -1.11% 1M

|

| -19.78% | O: -5.13% H: 5.41% C: 3.46%
NVS | News | $95.12 0.81% -1.18% 2.4M

|

Health Technology

| -2.58% | O: 0.45% H: 0.75% C: 0.46%
ORTX | $16.7 0.0% 370K

|

Health Technology

| 2.15% | O: 0.18% H: 0.43% C: 0.25%
GBIO | News | $2.805 0.18% 0.18% 150K

|

Health Technology

| 57.87% | O: 5.62% H: 3.72% C: -4.26%
BIIB | $194.1 -0.14% -0.15% 1.1M

|

Health Technology

| -21.13% | O: 0.59% H: 1.35% C: 0.6%
AMGN | News | $271.98 1.13% 1.12% 2.1M

|

Health Technology

| -0.08% | O: 1.83% H: 0.04% C: -1.13%
ADAP | $1.03 5.46% 5.17% 690K

|

Health Technology

| 101.0% | O: -0.46% H: 5.56% C: -1.12%
ABEO | News | $7.4 -2.25% -2.3% 480K

|

Health Technology

| 59.65% | O: 0.65% H: 2.59% C: 0.86%
america therapy growth market

See all

Last 15 days Sec forms

File Id	Form	Published Date	Transaction Date	Direction	Code	Amount Transacted	Owned Amount
0000950170-24-007089	4	2024-01-24	2024-01-24	Sell	D	46000	0
0000950170-24-007087	4	2024-01-24	2024-01-24	Sell	D	46000	0
0000950170-24-007087	4	2024-01-24	2024-01-24	Sell	D	44391	0

Your Today's Watch List

Sign in to create a watchlist

Gainers vs Losers

75%

25%

Top 10 Gainers

MTTR | News M | $4.78 174.71% 63.6% 72M

|

AGBA | $2.565 105.2% 51.27% 200M

|

MLEC | $2.44 74.29% 42.62% 78M

|

EDBL | News | $6.28 67.02% 40.13% 16M

|

ATGL | $2.91 48.81% 32.8% 180K

|

ZAPP | $0.2175 47.16% 32.05% 16M

|

ONFO | $0.6075 38.38% 27.74% 7.3M

|

VIVK | $1.48 38.32% 27.7% 530K

|

Professional, Scientific, and T...

MNTS | $0.5 35.69% 26.3% 4.8M

|

SDIG A | $3.635 35.13% 26.0% 1M

|

Last 48 Hours Insiders Buying

MCFT P 26039 | $21.5 1.9% 1.86% 110K

|

Consumer Durables

| 00:00
YORW P 29 | $35.43 1.03% 1.02% 66K

|

| 19:01
VUZI P 14500 | $1.35 11.57% 10.37% 890K

|

Electronic Technology

| 17:00
BANF P 256 | $91.28 2.24% 2.18% 150K

|

| 15:30
RMCF | $3.56 0.28% 0.28% 11K

|

Consumer Non-Durables

| 20:10

12 months watchlist earnings calendar